In a preclinical study, ONO-7475 (AXL/MER inhibitor) plus osimertinib overtly reduced tumor size and suppressed tumor growth compared to osimertinib alone, or combination therapy after acquisition of osimertinib resistance in AXL-overexpressing EGFR-mutated NSCLC xenograft models (68). Here, EGFR is linked to neoplasm.